Novel Genetic Variants of Promoter in Gestational Diabetes Mellitus and its Molecular Regulation in Adipogenesis.

Peroxisome proliferator-activated receptor γ2 () is a nuclear hormone receptor of ligand-dependent transcription factor with a key role in adipogenesis and insulin sensitization in diabetes mellitus. In this study, we investigated genetic variants in promoter, its association with gestational diabetes mellitus (GDM), and its molecular regulation. promoter and start codon (-2,091 to +82 bp) from 400 pregnancies with GDM and 400 gestational-age matched control pregnancies were sequenced.

Development of noninvasive prenatal diagnosis of trisomy 21 by RT-MLPA with a new set of SNP markers.

Introduction: Placental mRNA can now be detected in maternal whole blood, raising the possibility of using maternal blood for noninvasive prenatal diagnosis (NIPD) of trisomy 21. We aimed to identify new mRNA-single nucleotide polymorphism (mRNA-SNP) markers suitable for use in reverse-transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) to develop a more reliable diagnostic method for trisomy 21 in Chinese subjects.

Materials And Methods: Using sequencing, we determined the status of SNPs in genes expressed in the placenta and calculated their heterozygote frequencies to determine which loci were suitable for use in RT-MLPA.

[Identification of risk factors related to the failure of immunization to interrupt hepatitis B virus perinatal transmission].

Objective: To explore the factors influencing failure of an immunization to interrupt perinatal (mother-to-child) transmission of hepatitis B virus (HBV).

Methods: Between June 2006 and March 2010, a total of 1355 pregnant women testing positive for the hepatitis B surface antigen (HBsAg), at gestational weeks 20 to 42, and without use of antiviral or immunomodulatory drugs during the pregnancy were prospectively recruited to the study. The mothers were given a choice of receiving hepatitis B immunoglobulin (HBIG; three 200 IU intramuscular injections give at four-week intervals starting from gestation week 28) or not.

[Intrauterine growth characteristics of twins and those twins discordant birthweight].

Objective: To investigate the intrauterine growth characteristics of twins and birthweight discordant twins (discordant twins).

Methods: Total of 1010 twin pregnancies (2020 fetuses) with complete delivery records from the Department of Obstetrics and Gynecology, the First and Third Affiliated Hospital of SUN Yat-sen University between January 1, 2000 and July 31, 2010 were studied retrospectively. One handred and ninteen cases (238 fetuses) with intrapair birthweight difference ≥ 25% were determined as the discordant twins group, and the other 891 cases (1782 fetuses) with intrapair birthweight difference < 25% were identified as the concordant twins group.

[Intrauterine HBV infection: risk factors and impact of HBV DNA].

Objective: To investigate the risk factors of intrauterine hepatitis B virus (HBV) infection and the impact of HBV DNA on the infection.

Methods: The serum levels of HBsAg, HbsAb, HBeAg, HBeAb, HBcAb and HBV DNA were determined in blood samples from 230 HBsAg-positive pregnant women and their newborns by enzyme-linked immunosorbent assay (ELISA) and fluorescence quantitative PCR (FQ-PCR), respectively. The newborns acquiring HBV infection via intrauterine transmission were selected as the case group and others as the control group.

[Relations of pre-pregnant weight and weight gain during pregnancy with pregnancy-induced hypertension and birth weight].

Objective: To determine the influence of pre-pregnant body mass index (BMI) and weight gain during pregnancy on the occurrence of pregnancy-induced hypertension (PIH) and birth weight.

Methods: Pre-pregnant BMI and pregnancy weight gain of 769 mothers giving full-term birth to a single baby for the first time were measured and the pregnancy outcomes were followed up.

Results: (1) The incidence of PIH and fetal macrosomia was significantly higher in the overweight group than in the normal weight and underweight groups (P<0.

Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection.

Aim: To evaluate the efficacy of hepatitis B immunoglobulin (HBIG) in interrupting hepatitis B virus (HBV) intrauterine infection during late pregnancy.

Methods: We allocated 112 HBsAg positive pregnant women into 2 groups randomly. Fifty seven cases in the HBIG group received 200 IU (unit) HBIG intramuscularly every 4 wk from the 28 wk of gestation to the time of delivery, while 55 cases in the control group received no special treatment.

Interruption of HBV intrauterine transmission: a clinical study.

Aim: To investigate the effect of hepatitis B virus (HBV) specific immunoglobin (HBIG) and lamivudine on HBV intrauterine transmission in HBsAg positive pregnant women.

Methods: Each subject in the HBIG group (56 cases) was given 200 IU HBIG intramuscularly (im.) every 4 weeks from 28-week (wk) of gestation, while each subject in the lamivudine group (43 cases) received 100 mg lamivudine orally (po.